FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Animals
Aromatase Inhibitors
/ therapeutic use
Breast Neoplasms
/ drug therapy
Cell Line, Tumor
Chromatin
/ genetics
Estrogen Receptor alpha
/ genetics
Female
Gene Expression Profiling
/ methods
Gene Expression Regulation, Neoplastic
Hepatocyte Nuclear Factor 3-alpha
/ chemistry
Humans
MCF-7 Cells
Mice, Nude
Models, Molecular
Mutation, Missense
Protein Domains
Xenograft Model Antitumor Assays
/ methods
ESR1 mutations
FOXA1 mutations
breast cancer
chromatin accessibility
endocrine therapy
epigenomics
estrogen receptor
pioneer transcription factor
transcription
transcriptomics
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
12 10 2020
12 10 2020
Historique:
received:
30
01
2020
revised:
30
06
2020
accepted:
07
08
2020
pubmed:
6
9
2020
medline:
9
3
2021
entrez:
5
9
2020
Statut:
ppublish
Résumé
Mutations in the pioneer transcription factor FOXA1 are a hallmark of estrogen receptor-positive (ER
Identifiants
pubmed: 32888433
pii: S1535-6108(20)30414-1
doi: 10.1016/j.ccell.2020.08.003
pmc: PMC8311901
mid: NIHMS1717601
pii:
doi:
Substances chimiques
Aromatase Inhibitors
0
Chromatin
0
Estrogen Receptor alpha
0
FOXA1 protein, human
0
Hepatocyte Nuclear Factor 3-alpha
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
534-550.e9Subventions
Organisme : NCI NIH HHS
ID : K00 CA212478
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA190642
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests J.L.V.M. is an employee at Inzen Therapeutics. M.Sallaku has received funds from Puma Biotechnology, AstraZeneca, Daiichi-Sankio, Immunomedics, Targimmune, and Menarini Ricerche, is a cofounder of Medendi.org and is on the advisory board of Menarini Ricerche. J.B. is an employee and shareholder of AstraZeneca, Board of Directors member of Foghorn Therapeutics, and is a past board member of Varian Medical Systems, Bristol-Myers Squibb, Grail, Aura Biosciences, and Infinity Pharmaceuticals. He has performed consulting and/or advisory work for Grail, PMV Pharma, ApoGen, Juno, Lilly, Seragon, Novartis, and Northern Biologics. He has stock or other ownership interests in PMV Pharma, Grail, Juno, Varian, Foghorn, Aura, Infinity, ApoGen, as well as Tango and Venthera, of which he is a co-founder. He has previously received Honoraria or Travel Expenses from Roche, Novartis, and Lilly. C.L.S. serves on the board of directors of Novartis, is a co-founder of ORIC Pharm and co-inventor of enzalutamide and apalutamide. He is a science advisor to Agios, Beigene, Blueprint, Column Group, Foghorn, Housey Pharma, Nextech, KSQ, Petra, and PMV. He was a co-founder of Seragon (purchased by Genentech/Roche, 2014). J.S.R.-F. is a consultant of Goldman Sachs and REPARE Therapeutics, a member of the Scientific Advisory Board of VolitionRx and Paige.AI, and an ad hoc member of the Scientific Advisory Board of Ventana Medical Systems, Roche, Genentech, Novartis, and InviCRO. C.S.V. has been the recipient of research grants from Ipsen Pharmaceuticals, MSD International, and Proctor & Gamble. E.T. has received Honoraria from AstraZeneca for invited lectures. P.R. has received consultation fees from Novartis, AstraZeneca, Foundation Medicine and institutional research funds from Grail, Novartis and Illumina. W.R.K. is a patent holder with KNAW, Organoid Technology shared with Hans Clevers.S.Kannan and C.S.V. are founder directors of SiNOPSEE Therapeutics and Aplomex. The other authors declare no competing interests.
Références
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nature. 2019 Jul;571(7765):413-418
pubmed: 31243372
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
J Clin Invest. 2019 Jul 2;129(8):3006-3017
pubmed: 31264969
Nature. 2012 May 16;486(7403):400-4
pubmed: 22722201
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Genome Biol. 2015 Aug 08;16:160
pubmed: 26253137
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6600-E6609
pubmed: 27791031
Endocrinology. 2011 Nov;152(11):4443-7
pubmed: 21933867
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
PLoS Comput Biol. 2013;9(8):e1003118
pubmed: 23950696
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
Mol Cell. 2015 Apr 2;58(1):21-34
pubmed: 25752574
PLoS One. 2014 Mar 07;9(3):e90776
pubmed: 24608339
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Cell Rep. 2019 Sep 24;28(13):3523-3534.e2
pubmed: 31553919
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Nature. 2012 Jan 04;481(7381):389-93
pubmed: 22217937
Cell. 2008 Mar 21;132(6):958-70
pubmed: 18358809
J Mol Biol. 1993 Dec 5;234(3):779-815
pubmed: 8254673
Front Oncol. 2013 Feb 14;3:20
pubmed: 23420418
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
J Mol Biol. 2017 Nov 24;429(23):3626-3634
pubmed: 29050852
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
pubmed: 26574453
Nature. 2019 May;569(7757):560-564
pubmed: 31118521
Nat Methods. 2018 Feb;15(2):134-140
pubmed: 29256493
Sci Transl Med. 2016 Apr 13;8(334):334ra53
pubmed: 27075627
Biophys J. 2007 Jun 1;92(11):3817-29
pubmed: 17351000
Cell Rep. 2019 Apr 2;27(1):294-306.e5
pubmed: 30943409
Biochemistry. 2015 Jan 13;54(1):32-46
pubmed: 25431995
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Oncogenesis. 2016 Jan 25;5:e189
pubmed: 26807644
BMC Cancer. 2014 Nov 10;14:826
pubmed: 25385074
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Oncotarget. 2017 Jul 20;8(48):83673-83683
pubmed: 29137373
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
PLoS One. 2013 May 02;8(5):e63419
pubmed: 23658826
Clin Cancer Res. 2019 Jan 15;25(2):674-686
pubmed: 30185420
Nat Genet. 2011 Jan;43(1):27-33
pubmed: 21151129
Nature. 2012 Jun 20;486(7403):405-9
pubmed: 22722202
Nucleic Acids Res. 2018 Jan 4;46(D1):D794-D801
pubmed: 29126249
J Clin Invest. 2012 Sep;122(9):3088-100
pubmed: 22886304
Nat Genet. 2013 Dec;45(12):1439-45
pubmed: 24185512
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
J Clin Invest. 2017 Apr 3;127(4):1126-1135
pubmed: 28368289
Mol Cell. 2016 Apr 7;62(1):79-91
pubmed: 27058788
Cell. 2016 Apr 21;165(3):593-605
pubmed: 27062924
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Cancer Cell. 2018 Feb 12;33(2):173-186.e5
pubmed: 29438694
Genome Res. 2011 Apr;21(4):555-65
pubmed: 21233399
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Protoc. 2016 Feb;11(2):347-58
pubmed: 26797458
Cancer Res. 2013 Dec 1;73(23):6856-64
pubmed: 24217577
Nat Methods. 2013 Dec;10(12):1213-8
pubmed: 24097267
EMBO J. 1998 Jan 2;17(1):244-54
pubmed: 9427758
Nat Rev Cancer. 2007 Nov;7(11):847-59
pubmed: 17943136
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Cell. 2005 Jul 15;122(1):33-43
pubmed: 16009131
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Nat Med. 2015 Apr;21(4):335-43
pubmed: 25822366
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Nature. 2019 Jul;571(7765):408-412
pubmed: 31243370
EMBO J. 2011 May 13;30(13):2569-81
pubmed: 21572391
Dev Biol. 2016 Dec 15;420(2):197-198
pubmed: 27983962
Sci Rep. 2019 Jun 27;9(1):9354
pubmed: 31249361
Nucleic Acids Res. 2019 Jan 8;47(D1):D766-D773
pubmed: 30357393
Nature. 2012 Apr 04;486(7403):395-9
pubmed: 22495314
Nature. 2012 Jun 10;486(7403):353-60
pubmed: 22722193
Nucleic Acids Res. 2018 Jun 20;46(11):5470-5486
pubmed: 29669022
EMBO Rep. 2017 Feb;18(2):319-333
pubmed: 28007765
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Nature. 2017 Jul 6;547(7661):55-60
pubmed: 28658208
Nature. 2015 Nov 19;527(7578):384-8
pubmed: 26550823
Genes Dev. 2011 Nov 1;25(21):2227-41
pubmed: 22056668
Oncotarget. 2016 Jul 12;7(28):43518-43533
pubmed: 27270657
Nat Methods. 2017 Oct;14(10):959-962
pubmed: 28846090
Science. 2017 Mar 24;355(6331):1324-1330
pubmed: 28336670
Nat Genet. 2012 Feb 26;44(4):426-9, S1
pubmed: 22366784
Nat Genet. 2020 Feb;52(2):198-207
pubmed: 31932695
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
Cell. 2011 Dec 9;147(6):1270-82
pubmed: 22153072
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490